| 5.75 0.02 (0.35%) | 03-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.71 | 1-year : | 7.84 |
| Resists | First : | 5.75 | Second : | 6.71 |
| Pivot price | 5.74 |
|||
| Supports | First : | 5.7 | Second : | 5.67 |
| MAs | MA(5) : | 5.75 | MA(20) : | 5.73 |
| MA(100) : | 5.54  |
MA(250) : | 5.85 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 100 | D(3) : | 100 |
| RSI | RSI(14): 57.5 | |||
| 52-week | High : | 12.96 | Low : | 3.73 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SNCE ] has closed below upper band by 32.9%. Bollinger Bands are 97.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 26 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.76 - 5.79 | 5.79 - 5.81 |
| Low: | 5.67 - 5.71 | 5.71 - 5.74 |
| Close: | 5.7 - 5.75 | 5.75 - 5.8 |
Science 37 Holdings, Inc. provides technology-based solutions to enable agile clinical trials and decentralized approaches. Its platform enables modern and digital approaches to clinical research by bringing together all parties, including the patient and trial investigators, nurses, coordinators, and sponsors to power workflows, centralize evidence generation, and harmonize data. Its platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating agile clinical trials; and extensive configuration to support virtually any phase of clinical study and any indication. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina.
Thu, 04 Apr 2024
Science 37® to Participate in Upcoming Investor Conferences - The Globe and Mail
Sun, 31 Mar 2024
WELL Health Technologies (OTCMKTS:WLYYF) vs. Science 37 (NASDAQ:SNCE) Head-To-Head Contrast - Defense World
Tue, 12 Mar 2024
eMed completes tender offer for all outstanding shares of Science 37 - PR Newswire
Tue, 27 Feb 2024
SCIENCE 37 HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC ... - Business Wire
Thu, 15 Feb 2024
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - PGTI, SNCE, JNPR - Markets Insider
Mon, 12 Feb 2024
eMed commences tender offer for Science 37 - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 6 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 16.8 (%) |
| Held by Institutions | 52.1 (%) |
| Shares Short | 14 (K) |
| Shares Short P.Month | 31 (K) |
| EPS | -21.4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.68 |
| Profit Margin | -206.9 % |
| Operating Margin | -60.5 % |
| Return on Assets (ttm) | -28.4 % |
| Return on Equity (ttm) | -118.6 % |
| Qtrly Rev. Growth | -8.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 9.99 |
| EBITDA (p.s.) | -9.93 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -48 (M) |
| Levered Free Cash Flow | -48 (M) |
| PE Ratio | -0.27 |
| PEG Ratio | 0 |
| Price to Book value | 0.66 |
| Price to Sales | 0.57 |
| Price to Cash Flow | -0.72 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|